Thermo Fisher Scientific is shedding its microbiology business to private equity firm Astorg nearly a year after initial ...

Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading ...

Both Seaport Therapeutics and Hemab Therapeutics are hoping to bring in around $180 million each from their public listings ...

Astellas Pharma has done some spring cleaning of its pipeline, dropping two phase 1 candidates and slamming the brakes on a ...

“Our study highlights the growing potential of advanced biomarker science, combined with machine learning, to detect cancers ...

A simple outpatient procedure currently used for type 2 diabetes patients in Europe can help those on Eli Lilly’s obesity ...

The 552 million pounds ($747 million) raised by British biotechs in the first quarter of the year has been hailed as a “sign ...

Tandem Diabetes Care issued an urgent medical device correction to upgrade the software of its Tandem Mobi insulin pumps that ...

Eli Lilly's $7 billion deal for Kelonia Therapeutics on Monday was just the latest example | Despite the recent “feeding ...